Fig. 5: Serotype-specific longitudinal peak fold enhancement levels of KD-382 over the 12-month observation period for each DENV serotype. | npj Vaccines

Fig. 5: Serotype-specific longitudinal peak fold enhancement levels of KD-382 over the 12-month observation period for each DENV serotype.

From: Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults

Fig. 5

Peak fold enhancement values are presented as means ± SD. Statistical significance was assessed using the non-parametric Kruskall–Wallis test, followed by pairwise comparisons of each time point from months 2 to 12 against month 1 as the reference group, using Dunn’s test.

Back to article page